American Diabetes Association
Resubmission_Supp_Mater_14May2024.pdf (304.78 kB)

Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth with Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study

Download (304.78 kB)
posted on 2024-07-02, 14:22 authored by Petter Bjornstad, Silva A. Arslanian, Tamara S. Hannon, Philip S. Zeitler, Jennie L. Francis, Alexandra M. Curtis, Ibrahim Turfanda, David A. Cox

OBJECTIVE: To examine changes in glomerular hyperfiltration and other measures of kidney function in youth with type 2 diabetes treated with dulaglutide or placebo.

RESEARCH DESIGN AND METHODS: Post hoc analysis was performed on kidney laboratory data from 154 youth (10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide.

RESULTS: Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (-5.8 vs. -0.1 mL/min/1.73 m2; P=0.016). Decreases in eGFR were observed primarily in participants with baseline glomerular hyperfiltration. At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P=0.014 and 0.004 vs. placebo, respectively).

CONCLUSIONS: Dulaglutide was associated with attenuated glomerular hyperfiltration and proteinuria in youth with type 2 diabetes. The impact of these changes on the risk of diabetic kidney disease is unclear.


Support for the AWARD-PEDS trial was provided by Eli Lilly and Company.


Usage metrics

    Diabetes Care


    Ref. manager